M. Restrepo (San Antonio, United States of America), L. Bos (Amsterdam, Netherlands)
Non-steroidal anti-inflammatory drug use and clinical outcomes of community-acquired pneumonia
D. Basille (Amiens, France), R. Thomsen (Aarhus, Denmark), M. Madsen (Aarhus, Denmark), P. Duhaut (Amiens, France), C. Andrejak (Amiens, France), V. Jounieaux (Amiens, France), H. SøRensen (Aarhus, Denmark)
|    |
A retrospective survival analysis of nursing and healthcare associated pneumonia in patients with resistant pathogens
K. Umeki (Yufu, Japan), K. Komiya (Yufu, Japan), Y. Usagawa (Yufu, Japan), Y. Takeno (Yufu, Japan), M. Yamasue (Yufu, Japan), S. Nureki (Yufu, Japan), M. Ando (Yufu, Japan), K. Hiramatsu (Yufu, Japan), J. Kadota (Yufu, Japan)
|  |
Hypoxemia as a determinant of hospitalization in patients with Community Acquired Pneumonia
A. Suresh (Sundaram Medical Foundation, Chennai, India), D. Thenmozhi (Sundaram Medical Foundation, Chennai, India), G. Nayan Sri (Sundaram Medical Foundation, Chennai, India)
| |
Association between clinical profile and etiologic agent of pneumonia
M. Costa (Oporto, Portugal), A. Cipriano (Oporto, Portugal), F. Videira (Oporto, Portugal), S. Valdoleiros (Oporto, Portugal), A. Machado (Oporto, Portugal), J. Gomes (Oporto, Portugal), M. Abreu (Oporto, Portugal), H. Bastos (Oporto, Portugal)
| |
Human metapneumovirus lower respiratory tract infections in adults: chest CT imaging features and their evolution
L. Marinari (Bryn Mawr, United States of America), W. Miller, Jr. (Philadelphia, United States of America), M. Danny (Bryn Mawr, United States of America)
| |
Data from the PROGRESS study - blood gene expression patterns predict severe outcome of community aqcuired pneumonia
S. Weis (Jena, Germany), H. Kirsten (Leipzig, Germany), E. Grunow (Jena, Germany), P. Ahnert (Leipzig, Germany), G. Nouailles (Berlin, Germany), M. Kiehntopf (Jena, Germany), P. Creutz (Berlin, Germany), M. Löffler (Leipzig, Germany), N. Suttorp (Berlin, Germany), M. Witzenrath (Berlin, Germany), M. Bauer (Jena, Germany), M. Scholz (Leipzig, Germany)
| |
Respiratory syncytial virus (RSV) disease in hospitalised adults in Europe: comparison of retrospective patient chart reviews of adults =65 (=65y) and
O. Launay (Paris, France), F. Thalhammer (Vienna, Austria), T. Harrer (Erlangen, Germany), A. Cheret (Issy-les-Moulineaux, France), G. De La Rosa (Raritan, United States of America), I. Sander (Cambridge, United States of America), R. Stolper (Cambridge, United States of America), J. Zakar (Cambridge, United States of America), K. Weber (Vienna, Austria)
| |
Outcomes characteristics in healthcare-associated pneumonia
B. Gonçalves (Coimbra, Portugal), S. Cabral (Coimbra, Portugal), A. Lopes (Coimbra, Portugal)
| |
Point of care respiratory viral testing (POCT): A novel service to target appropriate antimicrobial prescription and improve antibiotic stewardship.
K. Roy (Watford, United Kingdom), K. Groom (Watford, United Kingdom), M. Knight (Watford, United Kingdom)
| |
Mortality associated factors of patients admitted due to flu during 2015-2016 and 2016-2017
A. Mangas Moro (Madrid, Spain), C. Carpio Segura (Madrid, Spain), E. Zamarrón De Lucas (Madrid, Spain), C. Prados Sánchez (Madrid, Spain), J. Arribas Peña (Madrid, Spain), B. Díaz Pollán (Madrid, Spain), R. Álvarez-Sala Walther (Madrid, Spain)
| |
The PROGRESS Study - Operationalization of Disease Severity and Prediction ofOutcome using the SOFA Score
P. Creutz (Berlin, Germany), P. Ahnert (Leipzig, Germany), M. Kiehntopf (Jena, Germany), H. Hossain (Giessen, Germany), M. Bauer (Jena, Germany), U. Völker (Greifswald, Germany), T. Chakraborty (Giessen, Germany), M. Witzenrath (Berlin, Germany), M. Löffler (Leipzig, Germany), M. Scholz (Leipzig, Germany), N. Suttorp (Berlin, Germany)
| |
Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia
B. Webb (Salt Lake City, United States of America), J. Sorensen (Salt Lake City, United States of America), A. Jephson (Salt Lake City, United States of America), I. Mecham (Salt Lake City, United States of America), N. Dean (Salt Lake City, United States of America)
| |
ERS guideline compliant antibiotics among hospitalized patients with Community-acquired pneumonia on the ward service
M. Restrepo (San Antonio, United States of America), S. Aliberti (Milan, Italy)
| |
The prognostic value of the Charlson’s comorbidity index in patients with bacteremic pneumonia
S. Song (Busan, Republic of Korea), S. Moon (Busan, Republic of Korea), S. Kim (Busan, Republic of Korea), M. Ko (Busan, Republic of Korea), J. Kim (Busan, Republic of Korea)
| |
Risk factors for antibiotic re-administration in patients with pneumonia during hospitalization.
S. Nishizawa (Fukuoka, Japan), K. Tobino (Fukuoka, Japan), M. Okahisa (Fukuoka, Japan), Y. Goto (Fukuoka, Japan), K. Murakami (Fukuoka, Japan), T. Sueyasu (Fukuoka, Japan), M. Munechika (Fukuoka, Japan), K. Yoshimine (Fukuoka, Japan)
| |
Risk factors for immunosuppression in hospitalized patients coming from the community with pneumonia: a worldwide perspective
M. Di Pasquale (Milano, Italy), G. Sotgiu (Sassari, Italy), A. Gramegna (Milano, Italy), D. Radovanovic (Milano, Italy), S. Terraneo (Milano, Italy), L. Reyes (San Antonio, United States of America), F. Blasi (Milano, Italy), M. Restrepo (San Antonio, United States of America), S. Aliberti (Milano, Italy)
| |
Evaluation of nursing and health care-associated pneumonia patients with poor performance status.
R. Hamanaka (Yufu, Japan), K. Umeki (Yufu, Japan), K. Komiya (Yufu, Japan), Y. Usagawa (Yufu, Japan), M. Yamasue (Yufu, Japan), S. Nureki (Yufu, Japan), M. Ando (Yufu, Japan), K. Hiramatsu (Yufu, Japan), J. Kadota (Yufu, Japan)
| |
Validation of C-Reactive protein and CURB-65 in the first hospital admission community acquired-pneumonia patient as a predictor of 30 days mortality
B. Foresto Buharman (Jakarta, Indonesia)
| |